NEW YORK (GenomeWeb) – iCubate announced yesterday that it has received CE mark for its first clinical assay, the iC-GPC assay and its platform, the iC-System, used for the rapid diagnosis of pathogenic bacteria associated with bloodstream infection. The CE mark provides an entry for iCubate to begin market integration into the European Union.